A Pilot Observational Clinical Survey: Impacts of Tahitian Noni Juice on the Quality of Life of Patients With Osteoarthritis

Not Applicable

Completed

• Conditions: Osteoarthritis
• Interventions: Dietary Supplement: Noni Juice

• Registration Number: NCT01070264
• Lead Sponsor: University of Illinois at Chicago

Brief Summary

Tahitian Noni Juice (TNJ) made from Morinda citrifolia (noni) fruits may provide a safe adjunctive treatment for osteoarthritis (OA) due to its anti-inflammatory and analgesic properties. In this study the investigators examined whether TNJ was able to improve the symptoms and quality of life (QOL) of OA patients. The investigators also sought to evaluate the tolerability and safety of TNJ.

This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-03
• Status Verified: 2007-02
• Primary Completion: 2007-02
• Study Completion: 2007-02
• Study First Submitted: 2010-02-16
• Study First Submitted QC: 2010-02-16
• Last Update Submitted: 2010-02-16
• Study First Posted: 2010-02-17
• Last Update Posted: 2010-02-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• adults aged 40 to 75 of both sexes with a physician diagnosis of OA of the hip or knee who were not taking prescription medicine for arthritis and were willing to drink 3 oz of TNJ daily for 12 weeks

Exclusion Criteria

• all others

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Noni Juice	Noni Juice	This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day

Primary Outcome Measures

Name	Time	Method
Quality of Life

Trial Locations

Locations (1)

University of Illinois-Chicago College of Medicine at Rockford; 🇺🇸 Rockford, Illinois, United States